- TABLE OF CONTENTS
- Multiple myeloma
- Other plasma cell dyscrasias
- Suggested reading
Suggested reading
On multiple myeloma
Attal M, Harousseau JL, Facon T, et al: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495–2502, 2003.
Barlogie B, Attal M, Crowley J, et al: Long-term follow-up of autotransplantation trials for multiple myeloma: Update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol 28:1209-1214, 2010.
Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory myeloma after single-agent thalidomide(Drug information on thalidomide): Identification of prognostic factors in a phase II study of 169 patients. Blood 98:492–494, 2001.
Bruno B, Rotta M, Patriarca F, et al: Nonmyeloablative allografting for newly diagnosed multiple myeloma: The experience of the Gruppo Italiano Trapianti di Midollo. Blood 113:3375–3382, 2009.
Cavo M, Tacchetti P, Patriarca F, et al: Bortezomib with thalidomide plus dexamethasone(Drug information on dexamethasone) compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomized phase 3 study. Lancet 376:2075-2085, 2010.
Dimopoulos M, Spencer A, Attal M, et al: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123–2132, 2007.
Facon T, Avet-Losieau H, Guillerm G, et al: Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97:1566–1571, 2001.
Fermand JP, Ravaud P, Chevret S, et al: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92:3131–3136, 1998.
Harousseau JL, Attal M, Avet-Loiseau H, et al: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin(Drug information on doxorubicin) plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol 20:4621-4629, 2010.
Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071–3076, 2001.
Jagannath S, Durie BG, Wolf J, et al: Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129:776–783, 2005.
Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 351:1860–1873, 2004.
Morgan GJ, Davies FE, Gregory WM, et al: First-line treatment with zoledronic acid(Drug information on zoledronic acid) as compared with clodronic acid(Drug information on clodronic acid) in multiple myeloma (MRC Myeloma IX): A randomised controlled trial. Lancet 376:1989-1999, 2010.
Munshi NC, Hideshima T, Carrasco D, et al: Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 103:1799–1806, 2004.
Rajkumar SV, Blood E, Vesole D, et al: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431–436, 2006.
Rajkumar SV, Hayman S, Lacy MQ, et al: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:781, 2005.
Rajkumar SV, Jacobus S, Callander NS, et al: Lenalidomide plus high-dose dexamethosone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 11:29–37, 2010.
Richardson PG, Sonneveld P, Schuster M, et al: Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood 110:3557–3560, 2007.
Richardson PG, Sonneveld P, Schuster MW, et al; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators: Bortezomib(Drug information on bortezomib) or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487–2498, 2005.
Richardson PG, Weller E, Lonial S, et al: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116:679–686, 2010.
Rosen LS, Gordon D, Antonio BS, et al: Zoledronic acid vs pamidronate(Drug information on pamidronate) in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7:377–387, 2001.
San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan(Drug information on melphalan) and prednisone(Drug information on prednisone) for initial treatment of multiple myeloma. N Engl J Med 359:906–917, 2008.
Spencer A, Prince HM, Roberts AW, et al: Consolidation therapy with low-dose thalidomide and prednisolone(Drug information on prednisolone) prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27:1788–1793, 2009.
Weber DM, Chen C, Niesvizky R, et al: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133–2142, 2007.
On other plasma cell dyscrasias
Dhodapkar MV, Jacobson JL, Gertz MA, et al: Prognostic factors and response to fludarabine therapy in Waldenström's macroglobulinemia: Results of US intergroup trial (Southwest Oncology Group S9003). Blood 98:41–48, 2001.
Dimopoulos MA, Zomas A, Viniou NA, et al: Treatment of Waldenström's macroglobulinemia with thalidomide. J Clin Oncol 19:3596–3601, 2001.
Sanchorawala V, Wright DG, Seldin DC, et al: An overview of the use of high-dose melphalan with autologous stem-cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 28:637–642, 2001.
Weber D, Treon SP, Emmanouilides C, et al: Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus panel recommendations for the Second International Workshop on Waldenstrom's macroglobulinemia. Semin Oncol 30:127–131, 2003.
Abbreviations in this chapter
APEX = Assessment of Proteasome Inhibition for Extending Remissions; CALGB = Cancer and Leukemia Group B; CIBMTR = Center for International Bone Marrow Transplant Registry; ECOG = Eastern Cooperative Oncology Group; EBMTR = European Bone Marrow Transplant Registry; IFM = Intergroupe Francophone du Myélome; IMWG = International Myeloma Working Group; MRC = Medical Research Council; NCI = National Cancer Institute; PETHEMA = Programa Español de Tratamientos en Hematología; SWOG = Southwest Oncology Group
